Incyte (INCY) Tax Provisions (2010 - 2026)
Incyte's (INCY) quarterly Tax Provisions came in at $165.9 million in Q2 2026, up 8.43% YoY from $153.0 million in Q2 2025, and up 311.99% on a QoQ basis from $40.3 million in Q1 2026.
Incyte (INCY) Tax Provisions (2010 - 2026) Analysis & Trends
Incyte (INCY) has 16 years of Tax Provisions data on file, last reported at $165.9 million in Q2 2026.
- Quarterly Tax Provisions rose 8.43% year-over-year to $165.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $355.0 million (down 9.35% YoY) and the FY2025 annual result came in at $377.8 million, up 33.02% from the prior year.
- Tax Provisions grew to $165.9 million in Q2 2026, from $40.3 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $165.9 million in Q2 2026 to a low of $30.2 million in Q1 2023.
- A 5-year average of $71.8 million and a median of $64.6 million in 2023 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2022 — Tax Provisions soared 206.06% — and 2026, when it tumbled 47.0%.
- Tracing INCY's Tax Provisions over 5 years: stood at $52.2 million in 2022, then surged by 33.98% to $69.9 million in 2023, then soared by 61.01% to $112.5 million in 2024, then retreated by 19.42% to $90.7 million in 2025, then soared by 83.0% to $165.9 million in 2026.
- The last three Tax Provisions figures came in at $165.9 million (Q2 2026), $40.3 million (Q1 2026), and $90.7 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 165.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 165.91 Mn |
| Mar 31, 2026 | 40.27 Mn |
| Dec 31, 2025 | 90.66 Mn |
| Sep 30, 2025 | 58.14 Mn |
| Jun 30, 2025 | 153.01 Mn |
| Mar 31, 2025 | 75.99 Mn |
| Dec 31, 2024 | 112.51 Mn |
| Sep 30, 2024 | 50.07 Mn |
| Jun 30, 2024 | 54.82 Mn |
| Mar 31, 2024 | 66.61 Mn |
| Dec 31, 2023 | 69.88 Mn |
| Sep 30, 2023 | 62.53 Mn |
| Jun 30, 2023 | 74.06 Mn |
| Mar 31, 2023 | 30.15 Mn |
| Dec 31, 2022 | 52.15 Mn |
| Sep 30, 2022 | 35.81 Mn |
| Jun 30, 2022 | 67.95 Mn |
| Mar 31, 2022 | 32.54 Mn |
| Dec 31, 2021 | -443.84 Mn |
| Sep 30, 2021 | 27.73 Mn |